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Abstract
Background: The incidence of Hodgkin lymphoma (HL) among HIV-infected individuals remains unchanged since the
introduction of combination antiretroviral therapy (cART). Recent epidemiological data suggest that CD4 count decline over
a year is associated with subsequent diagnosis of HL. In an era of economic austerity monitoring the efficacy of cART by CD4
counts may no longer be required where CD4 count.350 cells/ml and viral load is suppressed (,50 copies/ml).
Methods: We sought to establish among our HIV outpatient cohort whether a CD4 count decline prior to diagnosis of HL,
whether any decline was greater than in patients without the diagnosis, and also whether other clinical or biochemical
indices were reliably associated with the diagnosis.
Results: Twenty-nine patients with a diagnosis of HL were identified. Among 15 individuals on cART with viral load ,50
copies/ml the change in CD4 over 12 months preceding diagnosis of HL was 282 cells/ml (95% CI 2163 to 23; p = 0.04).
Among 18 matched controls the mean change was +5 cells/ml, 95% CI 270 to 80, p = 0.89). The decline in CD4 over the
previous 6–12 months was somewhat greater in cases than controls (mean difference in change 255 cells/ml, 95% CI 2151
to 39; p = 0.25). In 26 (90%) patients B symptoms had been present for a median of three months (range one–12) before
diagnosis of HL.
Conclusions: The CD4 count decline in the 12 months prior to diagnosis of Hodgkin lymphoma among HIV-infected
individuals with VL,50 copies/ml on cART was not significantly different from that seen in other fully virologically
suppressed individuals in receipt of cART and who did not develop HL. All those who developed HL had B symptoms and/or
new palpable lymphadenopathy, suggesting that CD4 count monitoring if performed less frequently, or not at all, among
those virologically suppressed individuals with CD4 counts .350 may not have delayed diagnosis.
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Introduction
While the incidence of AIDS-defining malignancies such as
Kaposi sarcoma and non-Hodgkin lymphoma has fallen since the
introduction of highly active antiretroviral therapy (HAART)
[1,2], the incidence of Hodgkin lymphoma has not decreased, and
remains elevated in HIV infected individuals [3–7]. Although
Hodgkin lymphoma in the context of HIV has been associated
with a more aggressive clinical course and a preponderance for
more aggressive histological subtypes [8,9], the prognosis of
Hodgkin lymphoma has improved and response rates are similar
to those in the HIV uninfected population [10–12].
An association between a falling CD4 cell count, not explained
by virological failure of HAART, and a diagnosis of Hodgkin
lymphoma has been described by the COHERE collaboration
[13]. The authors of that study proposed monitoring of CD4
counts and that a declining CD4 count might alert clinicians to the
possibility of Hodgkin lymphoma. However, a transient CD4
decline to ,350 cells/mm3 among virologically suppressed
patients is common [2,14] and, given the low incidence of
Hodgkin lymphoma among HIV-infected patients in Northern
Europe, it is possible that a transient decline in CD4 count may
trigger clinicians to undertake unnecessary investigations and
follow up.
We reviewed the CD4 dynamics, HAART history and clinical
features in virologically suppressed patients with HIV-associated
Hodgkin lymphoma and among matched controls to assess
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whether a CD4 count decline in virologically suppressed patients
was indicative of development of Hodgkin lymphoma, and to
identify if such a decline, if present, was associated with any
clinical or laboratory markers suggestive of Hodgkin lymphoma.
Materials and Methods
We undertook a retrospective cohort study of all HIV-associated
Hodgkin lymphoma diagnoses at our University-affiliated hospital-
based service in London, between 1996 and 2012. Mortimer
Market Centre and University College London Hospitals provide
HIV care to over 4,000 individuals in North central London,
United Kingdom (UK). Patients were managed according to UK
National Guidelines, with clinical review and CD4 monitoring
every three to six months [15]. CD4 lymphocyte count monitoring
was done in laboratory facilities (accredited to UK national
standards) at University College London Hospitals. The same
assay was used throughout the study and the laboratory is
accredited for CD4 measurements with QC performed regularly.
All CD4 counts are drawn and processed in the same working day.
Antiretroviral regimens were prescribed according to UK national
guidelines [15]. In the United Kingdom retrospectively obtained
anonymised NHS data used for audit and service improvement
purposes does not require ethical approval.
For each individual with Hodgkin lymphoma data were
extracted from paper case note review and interrogation of
electronic patient records, including viral load, antecedent CD4
dynamics (absolute CD4 count) prior to diagnosis of Hodgkin
lymphoma, as well as clinical and laboratory parameters. All
patients in the cohort who received HAART did so with two
nucleoside reverse transcriptase inhibitors and one non-nucleoside
reverse transcriptase inhibitor, a boosted protease inhibitor, or an
integrase inhibitor. Individuals with a fully suppressed viral load
(,50 copies/ml) and in receipt of HAART at diagnosis of
Hodgkin lymphoma were matched with controls who were
attending the outpatient clinic at Mortimer Market Centre, over
the same time interval and who were also in receipt of HAART
and had a fully suppressed viral load, and who did not
subsequently develop Hodgkin lymphoma. For each of these
control patients equivalent data was abstracted from case notes
and electronic patient records, relating to a ‘diagnosis date’ close to
diagnosis in the matched case and 12 months prior. Controls were
matched to cases on the basis of age (66 months), gender, and
CD4 lymphocyte count (6100 cells/mm3) at the earliest date (6, 9
or 12 months) prior to the ‘diagnosis’ date for which there was a
value available for both cases and controls. Where possible two
controls were matched to each case.
The Fisher’s exact test (two-tailed) was used to compare
proportions; the matched pairs Students’ T-test was used to
compare CD4 counts at baseline and at diagnosis for cases and
controls separately. These tests were carried out in GraphPad
Prism v4.01 (GraphPad Software Inc, San Diego, USA). To
compare the change in CD4 over time in cases with their matched
controls, linear regression with the change in CD4 as outcome
variable and case or control status as predictor was used, and
generalised estimating equations in Stata 12 (StataCorp LP,
College Station, USA) provided robust standard errors that
recognised the matching. Analysis of change in CD4 count in
cases was based on the change from the earliest date (6, 9, or 12
months) prior to diagnosis for which the CD4 count was measured
to diagnosis, and for comparison of cases to controls change from
the earliest date where the CD4 was measured for both case and
matched control(s) was analysed. A p-value of ,0.05 was
considered significant.
Results
Demographics and Presentation
Between January1996 and May 2012 a histologically-confirmed
diagnosis of Hodgkin lymphoma was made in 29 HIV-infected
patients: 27 (93%) were male and six (21%) were Black African.
Eighteen were men who have sex with men and two were
intravenous drug users. Three patients were co-infected with
Hepatitis B and two were co-infected with Hepatitis C. Their
median age was 41 years (range 26–61) and median time from
diagnosis of HIV infection to diagnosis of Hodgkin lymphoma was
67 months (range 0–320). No patient received interferon-c and
none started co-trimoxazole. Fifteen patients were receiving
HAART and were fully suppressed (VL,50), fourteen patients
were not in receipt of HAART and had detectable viral loads.
Fifteen patients, fully suppressed (VL,50) were identified. These
cases were matched to 18 control patients (also virologically
suppressed, who presented at the same time, were on HAART and
who did not develop HL).
At diagnosis of Hodgkin lymphoma, eighteen individuals had
stage IVB, two IVA, four IIIB, three IIB, one 1A and one stage 1B
disease. Seventeen (59%) had bone marrow involvement; one
patient did not undergo bone marrow examination, and this was
the only site of positive histology in 7/29 (24%) episodes of
Hodgkin lymphoma. At diagnosis of Hodgkin lymphoma 13
patients had a 18FDG PET-CT scan. Three patients with
histologically-confirmed bone marrow involvement had 18FDG
PET-CT scans suggestive of bone marrow infiltration. Of the
other ten patients with no evidence of bone marrow involvement
on 18FDG PET-CT, five had Hodgkin lymphoma on bone
marrow biopsy.
Among patients with advanced disease (Stage III/IV, n= 24)
the median lymphoma prognostic score (IPS) [16] of the group at
diagnosis was 3 (IQR 2–4), and 67% had a score of $3, similar to
that described in other UK centres [12]. Among the 12
virologically–suppressed patients with advanced disease the
median IPS was 3 (IQR 2.75–4); in three patients IPS ,3 and
in nine IPS $3. All but two patients had a complete response: of
the two patients who relapsed, one had a score of 5 and the other a
score of 2. The latter patient died of Hodgkin lymphoma while the
former achieved a good outcome.
Dynamics of CD4 Counts Preceding Diagnosis of
Hodgkin Lymphoma
Seventeen (59%) individuals had started HAART prior to
diagnosis of Hodgkin lymphoma (median duration was 3.5 years,
IQR 1.5–9.5 years). Fifteen (52%) individuals had a plasma HIV
RNA ,50 copies/ml at diagnosis of Hodgkin lymphoma; HIV
RNA was .50 copies/ml (median 50,500 copies/ml, IQR
29,375–177,100 copies/ml) in 12; plasma HIV RNA was not
recorded in two individuals. Median CD4 count at diagnosis of
Hodgkin lymphoma was 270 cells/ml (IQR 153–368). Median
CD4 count in those with plasma HIV RNA ,50 copies/ml was
320 cells/ml (IQR 188–368), and 240 cells/ml (IQR 150–330) in
those with plasma HIV RNA .50 copies/ml.
There was a significant fall in CD4 count over the 6–12 months
prior to diagnosis of Hodgkin lymphoma (mean change 2128
cells/ml, 95% CI 2194 to 264; p = 0.001), Figure 1. Among 17
patients receiving HAART at diagnosis of Hodgkin lymphoma
CD4 counts also declined, (mean change=289 cells/ml, 95% CI
2153 to 22; p = 0.04). When analysis was restricted to the 15
patients with consistent plasma HIV RNA ,50 copies/ml in the
12 months preceding diagnosis of Hodgkin lymphoma results were
similar; mean change in CD4 count was 282 cells/mm3 (95% CI
Diagnosis of HIV-Associated Hodgkin Lymphoma
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2163 to 23; p= 0.04), Figure 2. The median number of CD4
count measurements per individual was 4 (IQR 2–5). There was
little change over time in CD4 counts amongst the 18 controls
(mean change = 5 cells/ml, 95% CI 270 to 80, p= 0.89). The
decline in CD4 over the previous 6–12 months was somewhat
greater in cases than controls (mean difference in change 255
cells/ml, 95% CI 2151 to 39; p = 0.25), Figure 2. Among those
with suppressed viral load (VL,50), only 7/15 were lymphopenic
at diagnosis of Hodgkin lymphoma. Six of the seven virologically
suppressed patients with lymphopenia had stage IVB disease and
one had stage IIIB disease. The median IPS in these patients was 3
(IQR 2.5–3.5). Among the eight patients who were virologically
suppressed but not lymphopenic three had Stage IVB, two had
stage IVA, two had stage IIB and one had stage 1A disease. The
median IPS in the non-lymphopenic patients with advanced
disease was 4 (IQR 3–4). Lymphopenia at diagnosis of Hodgkin
lymphoma was not associated with stage of disease (p = 0.57) or
IPS (p= 0.61). We found a trend towards association between
lymphopenia at diagnosis of Hodgkin lymphoma and CD4 decline
in the 12 months prior to diagnosis (p = 0.11). The mean change in
CD4 count in the seven lymphopenic patients was 2142 cells/ml
(95% CI 2244 to 240), and 230 cells/ml (95% CI 2124 to +64)
in the eight non-lymphopenic patients, However, the difference
did not reach statistical significance (p= 0.1393). The CD4 decline
was normally distributed (data not shown) in the subgroups
considered.
Clinical and Biochemical Indices in Patients with Hodgkin
Lymphoma
In 26 (90%) patients B symptoms had been present for a median
of 3 months (range 1–12). Three patients did not have B symptoms
(all were on HAART); one had Stage IA disease and symptoms of
less than one month duration, one had Stage IVA disease and no
change in CD4 count, and one had a fall in CD4 lymphocyte
count without B symptoms and multiple hematological and
biochemical abnormalities prior to diagnosis: all three had new
palpable peripheral lymphadenopathy. No controls developed B
symptoms or new palpable lymphadenopathy.
Nineteen patients had anaemia and or thrombocytopenia prior
to diagnosis of Hodgkin lymphoma. Cytopenias at diagnosis were
not associated with bone marrow involvement (p = 0.47). One of
the controls (6%) developed new cytopenias, which were transient.
Discussion
The incidence of Hodgkin lymphoma has not fallen in HIV
infected patients in the era of HAART [3–5]. One of the main
challenges for clinicians is to rapidly make a diagnosis of Hodgkin
lymphoma among patients with non-specific symptoms such as
fever, sweats and weight loss. In the COHERE study patients with
Hodgkin lymphoma and who were in receipt of HAART lost 98
CD4 lymphocytes (95% CI, 2159 to 236 cells) in the year
preceding diagnosis whilst maintaining viral suppression on
HAART [13]. In the present study we saw a similar decline in
CD4 count over this period among patients receiving HAART
and who were virologically suppressed. No significant change in
CD4 count was observed in matched controls. Notably no
individuals received interferon-c nor started co-trimoxazole during
the study period. Although a minority received didanosine or
zidovudine these agents were not started during the year preceding
the diagnosis of Hodgkin lymphoma. Therefore the observed fall
in CD4 count in patients with Hodgkin lymphoma cannot be
ascribed to drugs that might have suppressed their CD4 counts.
Data from high income settings suggest that CD4 monitoring is
not required in addition to routine viral load measurement when
CD4 counts are above 350 cells/ml and viral suppression has been
achieved [14,17]. With increasing focus on health care efficiency,
such findings will lead to far fewer lymphocyte subset assays being
performed. Given the results from the COHERE study (mean
decline in CD4 count in the year before diagnosis of Hodgkin
lymphoma in virologically suppressed patients reciving HAART
was 98 cells/ml) [13] and other recent data from Italy showing a
mean CD4 count decline of 99 cells/ml in the year before diagnosis
of Hodgkin lymphoma, compared with a mean increase of 37
cells/ml in controls [7], it might be inferred that an opportunity
will be missed to make the diagnosis. However, our data suggest
that stopping routine monitoring of CD4 counts would not be
expected to result in diagnosis of Hodgkin lymphoma being missed
or delayed if regular clinical-follow up is maintained, and clinicians
are aware of the importance of monitoring for B symptoms, new
palpable peripheral lymphadenopathy or abnormal blood bio-
chemistry/cytopenias. New palpable lymphadenopathy and B
symptoms would have captured all cases of Hodgkin lymphoma in
our cohort. The majority of our patients had bone marrow
involvement and of note a substantial minority had isolated bone
marrow disease, highlighting the importance of this examination
as part of a work up for suspected Hodgkin lymphoma. It is now
our practice to educate clinicians and patients to be alert for the
onset and significance of B symptoms and for the development of
new lymphadenopathy.
Our study is limited by the relatively small sample size and its
retrospective nature. Larger prospective studies of patients with
suppressed viral loads are indicated to evaluate the utility of
monitoring for classical symptoms and signs of lymphoma (B
symptoms, cytopenias, lymphadenopathy) compared with the
utility of CD4 count monitoring for early detection of patients
with Hodgkin lymphoma.
In summary, this study showed that there was a CD4 count
decline in the 12 months prior to diagnosis of Hodgkin lymphoma
among HIV-infected individuals who were fully virologically
suppressed and in receipt of HAART. All those who developed
Figure 1. Change in CD4 count in the twelve months preceding
diagnosis of Hodgkin Lymphoma amongst 29 patients studied.
Data points are median CD4 in the cohort at each time point and hairs
represent interquartile range. Numbers in parentheses represent the
number of observations at each time point.
doi:10.1371/journal.pone.0087442.g001
Diagnosis of HIV-Associated Hodgkin Lymphoma
PLOS ONE | www.plosone.org 3 February 2014 | Volume 9 | Issue 2 | e87442
Hodgkin lymphoma had B symptoms and/or new palpable
lymphadenopathy.
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